{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:12:58Z","timestamp":1792660378571,"version":"4.5.0"},"reference-count":35,"publisher":"European Respiratory Society (ERS)","issue":"4","content-domain":{"domain":["ersjournals.com"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2012,7,19]]},"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:p>In preterm human infants, briefly elevated concentrations of oxygen are associated with a prolonged increase in blood chemokine concentrations and the development of bronchopulmonary dysplasia (BPD). Caffeine given to preterm infants for the prevention or treatment of apnoea has been shown to reduce the rate of BPD.<\/jats:p><jats:p>We tested the hypotheses that infant rats exposed to a combination of caffeine and hyperoxia would be less susceptible to lung injury than those exposed to hyperoxia alone and that caffeine decreases the pulmonary tissue expression of chemokines and leukocyte influx following hyperoxia.<\/jats:p><jats:p>Using 6-day-old rat pups, we demonstrated that 24 h of 80% oxygen exposure caused pulmonary recruitment of neutrophils and macrophages. High levels of oxygen upregulated the expression of: the CXC chemokines, cytokine-induced neutrophil chemoattractant-1 and macrophage inflammatory protein-2; the CC-chemokine monocyte chemoattractant protein-1; the pro-inflammatory cytokines tumour necrosis factor-\u03b1 and interleukin-6, as measured by realtime PCR after the administration of caffeine (10 mg\u00b7kg<jats:sup>\u22121<\/jats:sup>body weight); and attenuated chemokine and cytokine upregulation, as well as the influx of CD11b<jats:sup>+<\/jats:sup>, ED-1<jats:sup>+<\/jats:sup>and myeloperoxidase<jats:sup>+<\/jats:sup>leukocytes.<\/jats:p><jats:p>These experiments suggest that protective effects of caffeine in the neonatal lung are mediated, at least in part, by reduction of pulmonary inflammation.<\/jats:p>","DOI":"10.1183\/09031936.00012412","type":"journal-article","created":{"date-parts":[[2012,8,12]],"date-time":"2012-08-12T00:25:52Z","timestamp":1344731152000},"page":"966-973","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":117,"title":["Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine"],"prefix":"10.1183","volume":"41","author":[{"given":"Ulrike","family":"Weichelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhuye","family":"Cay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sifringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"B\u00fchrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Endesfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2012,8,9]]},"reference":[{"key":"2024102021154165000_41.4.966.1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-2959"},{"key":"2024102021154165000_41.4.966.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra067279"},{"key":"2024102021154165000_41.4.966.3","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199912000-00007"},{"key":"2024102021154165000_41.4.966.4","first-page":"CD001146","article-title":"Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants","volume":"1","author":"Halliday","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102021154165000_41.4.966.5","first-page":"CD007836","article-title":"Animal derived surfactant extract for treatment of respiratory distress syndrome","volume":"2","author":"Seger","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102021154165000_41.4.966.6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0434"},{"key":"2024102021154165000_41.4.966.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906243402505"},{"key":"2024102021154165000_41.4.966.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054065"},{"key":"2024102021154165000_41.4.966.9","first-page":"CD000140","article-title":"Methylxanthine treatment for apnea in preterm infants","volume":"3","author":"Henderson-Smart","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102021154165000_41.4.966.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.09.069"},{"key":"2024102021154165000_41.4.966.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-009-0961-9"},{"key":"2024102021154165000_41.4.966.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2003.12.007"},{"key":"2024102021154165000_41.4.966.13","first-page":"L110","article-title":"Functional and pathological effects of prolonged hyperoxia in neonatal mice","volume":"275","author":"Warner","year":"1998","journal-title":"Am J Physiol"},{"key":"2024102021154165000_41.4.966.14","doi-asserted-by":"publisher","DOI":"10.1159\/000092868"},{"key":"2024102021154165000_41.4.966.15","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262"},{"key":"2024102021154165000_41.4.966.16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1203\/00006450-199606000-00001","article-title":"Changes in structure, mechanics, and insulin-like growth factor-related gene expression in the lungs of newborn rats exposed to air or 60% oxygen","volume":"39","author":"Han","year":"1996","journal-title":"Pediatr Res"},{"key":"2024102021154165000_41.4.966.17","first-page":"90","article-title":"Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats","volume":"299","author":"Auten","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2024102021154165000_41.4.966.18","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.6.9911020"},{"key":"2024102021154165000_41.4.966.19","first-page":"365","article-title":"Cytokine response during hyperoxia: sequential production of pulmonary tumor necrosis factor and interleukin-6 in neonatal rats","volume":"2","author":"Ben-Ari","year":"2000","journal-title":"Isr Med Assoc J"},{"key":"2024102021154165000_41.4.966.20","doi-asserted-by":"publisher","DOI":"10.1007\/BF01958074"},{"key":"2024102021154165000_41.4.966.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2006.03.004"},{"key":"2024102021154165000_41.4.966.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.12.040"},{"key":"2024102021154165000_41.4.966.23","unstructured":"Miller JM Fanaroff AA Martin JR . Respiratory disorders in preterm and term infants. In : Fanaroff AA Martin RJ , eds. Neonatal\u2013Perinatal Medicine. Diseases of the Fetus and Infant. Maryland Height, Mosby, 1997; pp. 1040\u20131065."},{"key":"2024102021154165000_41.4.966.24","unstructured":"Roberts R . Methylxanthine therapy: caffeine and theophylline. In : Roberts R , ed. Drug Therapy in Infants: Pharmacologic Principles and Clinical Experience. Philadelphia, WB Saunders, 1984; pp. 19\u2013137."},{"key":"2024102021154165000_41.4.966.25","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e31818d66b1"},{"key":"2024102021154165000_41.4.966.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2004.06.005"},{"key":"2024102021154165000_41.4.966.27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.11.7431"},{"key":"2024102021154165000_41.4.966.28","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200210280-00023"},{"key":"2024102021154165000_41.4.966.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.06.051"},{"key":"2024102021154165000_41.4.966.30","first-page":"227","article-title":"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat","volume":"13","author":"Bortolotti","year":"1985","journal-title":"Drug Metab Dispos"},{"key":"2024102021154165000_41.4.966.31","first-page":"285","article-title":"In vivo and perfused liver caffeine kinetics in the rat","volume":"69","author":"Bortolotti","year":"1990","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"2024102021154165000_41.4.966.32","first-page":"527","article-title":"International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol Rev"},{"key":"2024102021154165000_41.4.966.33","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1983"},{"key":"2024102021154165000_41.4.966.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2010.05.016"},{"key":"2024102021154165000_41.4.966.35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002907"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00012412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:38:49Z","timestamp":1740379129000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00012412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,9]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,3,31]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1183\/09031936.00012412"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00012412","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,9]]}}}